INSYS Therapeutics Inc

Quick facts

Marketed products

• Fentanyl sublingual spray

Phase 2 pipeline

• LEP-ETU

Phase 1 pipeline

• Actiq® 400 µg transmucosally · Pain Management
  Fentanyl acts by binding to opioid receptors, primarily mu-opioid receptors, in the central nervous system to produce analgesia and euphoria.
• Dronabinol 30 mg
• Fentanyl 400 µg sublingual spray
• LE-DT
• LErafAON
• LErafAON-ETU
• Liposome-encapsulated SN38
• SL film
• Temozolomide with radiation therapy

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• INSYS Therapeutics Inc portfolio CI brief
• INSYS Therapeutics Inc pipeline updates RSS